Genmab (Otc) ((GMAB)), Biontech Se Sponsored Adr ((BNTX)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Genmab and BioNTech SE are collaborating on a clinical study to evaluate the efficacy and safety of a new treatment regimen for metastatic colorectal cancer (mCRC). The study, titled A Phase I/II, Randomized, Multi-site Trial to Investigate the Efficacy and Safety of BNT314 in Combination With BNT327 and Chemotherapy in Participants With Metastatic Colorectal Cancer, aims to assess the potential benefits of combining BNT314, an immune system booster, with BNT327, an immune checkpoint inhibitor, and standard chemotherapy.
The study involves testing BNT314 and BNT327, both administered via intravenous infusion, alongside standard chemotherapy treatments. BNT314 is designed to enhance the immune system’s ability to fight cancer, while BNT327 serves as an immune checkpoint inhibitor to prevent cancer cells from evading immune detection.
This interventional study is randomized and sequential, focusing on treatment as its primary purpose. It is open-label in its initial phases, with some blinding in later stages to ensure unbiased results.
The study began on July 9, 2025, with its latest update on October 24, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.
The outcome of this study could significantly impact the stock performance of Genmab and BioNTech, as positive results may boost investor confidence and market value. With the competitive landscape of cancer treatments, advancements in this study could position these companies favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.